electroCore today disclosed the results of a peer‑reviewed study titled “Non‑Invasive Transcutaneous Vagal Nerve Stimulation Enhances Mood, Task Performance, and Learning in a High‑Stress Military Training Environment.” The study, which will be presented at the Applied Human Factors and Ergonomics Conference on December 8, 2025, evaluated the TAC‑STIM device in 70 active‑duty United States Air Force trainees and found statistically significant reductions in distress (p < 0.001), increases in perceived ability (p = 0.020), higher energy levels (p = 0.002), and objective performance gains (group main effect p = 0.020). These findings are the first to demonstrate the device’s benefits in an actual high‑stress training setting.
The study’s results validate electroCore’s core claim that TAC‑STIM can enhance cognitive performance and mood regulation under demanding conditions. By showing measurable improvements in both subjective and objective metrics, the data provide a strong evidence base that the device can support force readiness and resilience. The fact that the study was conducted in a real military environment, rather than a laboratory, strengthens the relevance of the findings for defense customers and underpins the company’s strategy to expand sales into law‑enforcement and high‑performance consumer markets.
In its most recent quarterly report, electroCore reported Q3 2025 revenue of $8.7 million, up 33 % year‑over‑year, and a net loss of $3.4 million, or $0.40 per share, compared with a $2.5 million loss ($0.31 per share) in Q3 2024. The revenue growth reflects increased demand for the company’s prescription and wellness products, while the widening loss highlights ongoing investment in product development and market expansion. The study announcement adds a new potential revenue stream that could offset the company’s current profitability challenges and accelerate the transition from a medical‑device focus to a broader bioelectronic‑technology portfolio.
CEO Dan Goldberger said, “TAC‑STIM represents a significant advancement in our mission to support those who serve. By enhancing force readiness, TAC‑STIM has the potential to make a substantial impact on the effectiveness and wellbeing of military personnel.” He added, “Beyond defense, tVNS / nVNS technology is well positioned for accelerated entry into consumer wellness, workplace productivity, and educational markets. Benefits such as enhanced focus, accelerated skill acquisition, improved mood, and reduced fatigue align with the expanding demand for cognitive augmentation tools in civilian domains.”
The bioelectronic medicine market, in which electroCore competes with companies such as Medtronic, Abbott, and Boston Scientific, is growing rapidly as electrical therapies are applied to a range of neurological and psychiatric conditions. electroCore’s TAC‑STIM device, with its non‑invasive design and proven efficacy in a high‑stress setting, positions the company to capture a share of this expanding market. The study’s positive results reinforce the company’s narrative of innovation and broaden the potential customer base beyond traditional medical indications.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.